P3 Health Partners (PIII) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Meeting conducted virtually with introductions of key officers and explanation of meeting procedures.
Agenda and rules of conduct provided on the virtual meeting webpage; voting and Q&A procedures explained.
Shareholder proposals
Four proposals presented: election of three Class II directors, ratification of BDO USA, P.C. as auditor, advisory approval of executive compensation, and approval for issuance of up to 3,341,130 shares upon warrant exercise.
Overview of voting outcomes
Quorum confirmed and all four proposals approved based on preliminary Inspector of Election report.
Final vote tally to be published within four business days in a Form 8-K filing.
Partial view of Summaries dataset, powered by Quartr API
Latest events from P3 Health Partners
- Q1 2026 delivered $3M net income and $26M adjusted EBITDA, but liquidity risks remain.PIII
Q1 202620 May 2026 - 2026 guidance targets $1.5B–$1.65B revenue and $20M–$60M adjusted EBITDA amid strategic growth.PIII
Investor presentation14 May 2026 - Key votes include director elections, auditor ratification, and approval of new share issuance.PIII
Proxy filing30 Apr 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and warrant share issuance.PIII
Proxy filing30 Apr 2026 - Board recommends approval of all proposals, including director elections and share issuance.PIII
Proxy filing20 Apr 2026 - Value-based care model targets $1.7B revenue and positive EBITDA in 2026, led by seasoned executives.PIII
Investor presentation30 Mar 2026 - 2026 outlook projects a $170M EBITDA improvement and 29,000 new Medicare Advantage members.PIII
Q4 202526 Mar 2026 - Operational focus and technology upgrades target margin growth and cash flow positivity by 2025.PIII
17th Annual LD Micro Main Event Conference13 Feb 2026 - Q2 revenue up 15% to $379M, but profitability declined and liquidity risks remain.PIII
Q2 20242 Feb 2026